NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Buclizine hydrochloride is an oral antihistamine tablet approved in 1957 for managing nausea, vomiting, and motion sickness. It functions as a first-generation H1-receptor antagonist with anticholinergic properties. The drug has been a long-standing symptomatic treatment in the antiemetic class.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial momentum; limited team expansion expected and significant focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on Buclizine are concentrated in Legal and regulatory compliance roles, reflecting the product's mature, post-LOE status requiring patent defense, generic litigation, and regulatory administration. This is a niche opportunity suitable for professionals focused on intellectual property strategy and regulatory affairs rather than commercial growth.
Legal
Worked on BUCLADIN-S at Stuart Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.